Nature Communications (Jun 2021)
COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants
- Pinja Jalkanen,
- Pekka Kolehmainen,
- Hanni K. Häkkinen,
- Moona Huttunen,
- Paula A. Tähtinen,
- Rickard Lundberg,
- Sari Maljanen,
- Arttu Reinholm,
- Sisko Tauriainen,
- Sari H. Pakkanen,
- Iris Levonen,
- Arttu Nousiainen,
- Taru Miller,
- Hanna Välimaa,
- Lauri Ivaska,
- Arja Pasternack,
- Rauno Naves,
- Olli Ritvos,
- Pamela Österlund,
- Suvi Kuivanen,
- Teemu Smura,
- Jussi Hepojoki,
- Olli Vapalahti,
- Johanna Lempainen,
- Laura Kakkola,
- Anu Kantele,
- Ilkka Julkunen
Affiliations
- Pinja Jalkanen
- Institute of Biomedicine, University of Turku
- Pekka Kolehmainen
- Institute of Biomedicine, University of Turku
- Hanni K. Häkkinen
- Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki University Hospital and University of Helsinki
- Moona Huttunen
- Institute of Biomedicine, University of Turku
- Paula A. Tähtinen
- Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku
- Rickard Lundberg
- Institute of Biomedicine, University of Turku
- Sari Maljanen
- Institute of Biomedicine, University of Turku
- Arttu Reinholm
- Institute of Biomedicine, University of Turku
- Sisko Tauriainen
- Institute of Biomedicine, University of Turku
- Sari H. Pakkanen
- Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki University Hospital and University of Helsinki
- Iris Levonen
- Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki University Hospital and University of Helsinki
- Arttu Nousiainen
- Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki University Hospital and University of Helsinki
- Taru Miller
- Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki University Hospital and University of Helsinki
- Hanna Välimaa
- Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki University Hospital and University of Helsinki
- Lauri Ivaska
- Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku
- Arja Pasternack
- Department of Physiology, University of Helsinki
- Rauno Naves
- Department of Physiology, University of Helsinki
- Olli Ritvos
- Department of Physiology, University of Helsinki
- Pamela Österlund
- Finnish Institute for Health and Welfare
- Suvi Kuivanen
- Department of Virology, University of Helsinki
- Teemu Smura
- Department of Virology, University of Helsinki
- Jussi Hepojoki
- Department of Virology, University of Helsinki
- Olli Vapalahti
- Department of Virology, University of Helsinki
- Johanna Lempainen
- Institute of Biomedicine, University of Turku
- Laura Kakkola
- Institute of Biomedicine, University of Turku
- Anu Kantele
- Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki University Hospital and University of Helsinki
- Ilkka Julkunen
- Institute of Biomedicine, University of Turku
- DOI
- https://doi.org/10.1038/s41467-021-24285-4
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 11
Abstract
Emerging SARS-CoV-2 variants contain mutations in the spike protein that may affect vaccine efficacy. Here, Jalkanen et al. show, using sera from 180 BNT162b2-vaccinated health care workers, that neutralization of SARS-CoV2 variant B.1.1.7 is not affected, while neutralization of B.1.351 variant is five-fold reduced.
